From: Prognostic models for breast cancer: a systematic review
 | Number of modelsa |
---|---|
Total | 58 models |
Types of models | |
 New models | 49 models |
 Modified models | 9 models |
Year of development | 1982–2016 |
 1982–1989 | 5 models |
 1990–1999 | 11 models |
 2000–2009 | 17 models |
 2010–2016 | 25 models |
Country of participants for model development | |
 Europe | 25 models |
 Asia | 13 models |
 North America | 12 models |
 Others | 1 model (Australia) |
 Unknown or from several trials | 7 models |
Method of model development | |
 Cox PH regression | 32 models |
 Artificial neural networks | 6 models |
 Decision tree | 4 models |
 Logistic regression | 3 models |
 Bayesian method | 3 models |
 Multistate model | 2 models |
 Support vector machine | 2 models |
 Others | 6 models |
Outcomes | |
 Mortality | 28 models |
 Recurrence | 23 models |
 Both | 7 models |
Predictors | |
 Age at diagnosis | 24 models |
 Nodal status | 49 models |
 Tumour size | 42 models |
 Tumour grade | 29 models |
 Lympho-vascular invasion (LVI) | 8 models |
 Stage | 8 models |
 ER status | 21 models |
 Progesterone receptor (PR) status | 10 models |
 HER2 status | 13 models |
 Treatment | 17 models |
 Others | Mitotic activity index (MAI), histological subtypes, comorbidity, menopausal status, etc. |
Presentation of model | |
 Regression formula | 13 models |
 Online tool | 8 models |
 Decision tree | 5 models |
 Nomogram | 4 models |
 Score chart | 1 model |
 No report | 27 models |
Number of risk groups | |
 5 | 3 models |
 4 | 3 models |
 3 | 9 models |
 2 | 6 models |
 No report/No risk group | 33 models |
Validation | |
 No validation | 11 models |
 Internal validation | 43 models |
 External validation | 17 models |